Abstract
Immunotherapy, including checkpoint blockade immunotherapy (CBI), has witnessed remarkable progress in cancer therapy. Nonetheless, significant obstacles to successful immunotherapy remain. Notably, tumour non-responsiveness to immunotherapy due to immunosuppressive tumour microenvironments (TMEs). To revitalize immunosuppressive TMEs various therapeutic strategies have been reported by researchers. Immunostimulatory adjuvant treatments (IAT) are the most widely investigated ones. Due to their biodegradability, compositional tenability, and inherent immune effectiveness, nanoscale metal-organic frameworks (nMOFs) with metal nodes and organic linkers can be used as versatile nanomaterials for IAT. This review summarizes the progress in nMOF-based tumour immunotherapy in promoting immunostimulatory TMEs. And in combination with other cancer immunotherapies to increase tumour immunogenicity and antitumor efficacy. Finally, the challenges of nMOFs in tumour immunotherapy are also discussed.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
